Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 12/20 | 0.56 |
| ▸ | CA2 known ✓ | P00918 | 12/20 | 0.56 |
| ▸ | CA12 known ✓ | O43570 | 4/20 | 0.46 |
| ▸ | CA4 known ✓ | P22748 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | GLA | P06280 | 1/20 | 0.83 |
| ▸ | HPGD | P15428 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | CA9 | Q16790 | 9/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL28262916 | 0.95 | TSHR (0.76) | TSHRRECQLGLAHPGDMAPK1 | |
| Zinc Ion SCHEMBL31471926 | 0.95 | TSHR (0.75) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL2634750 | 0.95 | — | — | |
| SCHEMBL17456497 | 0.95 | TSHR (0.75) | TSHRRECQLGLAHPGDMAPK1 | |
| Lithium Ion SCHEMBL17456624 | 0.95 | TSHR (0.75) | TSHRRECQLGLAHPGDMAPK1 | |
| Potassium Ion SCHEMBL6534824 | 0.95 | TSHR (0.75) | TSHRRECQLGLAHPGDMAPK1 | |
| Ammonia Solution, Strong SCHEMBL635965 | 0.93 | TSHR (0.72) | TSHRRECQLGLAHPGDMAPK1 | |
| Amylosulfuric Acid SCHEMBL1134661 | 0.93 | RECQL (0.95) | TSHRRECQLGLAHPGDMAPK1 | |
| Ethylene Glycol SCHEMBL7705253 | 0.91 | TSHR (0.70) | TSHRRECQLGLAHPGDMAPK1 | |
| SCHEMBL23387500 | 0.91 | RECQL (1.00) | TSHRRECQLGLAHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512475-A2 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3651734-B1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-11-13 | — | — | EP | claimed |
| US-20240148700-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | ALDEYRA THERAPEUTICS, INC. | 2024-05-09 | — | — | US | claimed |
| US-11975017-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | claimed |
| US-20240091251-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-03-21 | — | — | US | claimed |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | claimed |
| US-20230189820-A1 | COMPOSITIONS FOR CONTROLLING ARTHROPODS | THE PROCTER & GAMBLE COMPANY | 2023-06-22 | — | — | US | claimed |
| EP-4132651-A1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBANUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2023-02-15 | — | — | EP | claimed |
| US-20220280549-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-09-08 | — | — | US | claimed |
| US-11266681-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | claimed |
| US-20160317494-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-03 | — | — | US | claimed |
| CN-103052386-B | Compositions containing tetracyclic compound | CHUGAI PHARMACEUTICAL CO.,LTD. (JP) | 2016-03-02 | — | — | CN | claimed |
| US-20140294740-A1 | ORAL CARE COMPOSITIONS | COLGATE-PALMOLIVE COMPANY (US) | 2014-10-02 | — | — | US | claimed |
| US-20140194344-A1 | FUSION PEPTIDE DESIGNED TO REDUCE PLAQUE BACTERIA AND YEAST IN THE ORAL CAVITY | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2014-07-10 | — | — | US | claimed |
| US-20120302601-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | NEURON SYSTEMS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| JP-2012500865-A | — | — | 2012-01-12 | — | — | JP | claimed |
| CN-102186643-A | Enhanced surfaces, coatings and related methods | INNOVA METERIALS LLC | 2011-09-14 | — | — | CN | claimed |
| EP-2328731-A1 | ENHANCED SURFACES, COATINGS, AND RELATED METHODS | Innova Dynamics, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| WO-2010022353-A1 | ENHANCED SURFACES, COATINGS, AND RELATED METHODS | INNOVA METERIALS, LLC (US) | 2010-02-25 | — | — | WO | claimed |
| US-4917985-A | SULFONATES AND SULFATES DISPERSED IN THERMOPLASTIC RESIN AND NONPOLAR LIQUID | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302601-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6H, PDE6D | CA1 4805/4885CA2 2516/4885CA12 3389/4885 |
| US-20220280549-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | CTDSP1, RNGTT, POLRMT | CA1 3296/4885CA2 2028/4885CA12 3304/4885 |
| US-11266681-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | CTDSP1, RNGTT, POLRMT | CA1 3296/4885CA2 2028/4885CA12 3304/4885 |
| US-20240091251-A1 | COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS | CTDSP1, RNGTT, POLRMT | CA1 3296/4885CA2 2028/4885CA12 3304/4885 |
| US-20160317494-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | CA1 102/4885CA2 940/4885CA12 614/4885 |
| US-20240148700-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6H, PDE6D | CA1 4805/4885CA2 2516/4885CA12 3389/4885 |
| US-20140194344-A1 | FUSION PEPTIDE DESIGNED TO REDUCE PLAQUE BACTERIA AND YEAST IN THE ORAL CAVITY | PAK5, LASP1, PAK1 | CA1 1711/4885CA2 1251/4885CA12 2529/4885 |
| US-11975017-B2 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | CTDSP1, RNGTT, POLRMT | CA1 3296/4885CA2 2028/4885CA12 3304/4885 |
| US-20240024341-A1 | INHALATION FORMULATIONS OF 1`-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | SLC29A1, SLC28A1, RNMT | CA1 835/4885CA2 428/4885CA12 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.